Patient outcomes post-pulmonary resection for synchronous bone-metastatic non-small cell lung cancer.
Surgery
bone metastasis
non-small cell lung cancer (NSCLC)
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
entrez:
29
10
2019
pubmed:
28
10
2019
medline:
28
10
2019
Statut:
ppublish
Résumé
The efficacy of curative-intent pulmonary resection for non-small cell lung cancer (NSCLC) patients with certain types of oligometastases, particularly brain and adrenal metastases, has previously been described. We investigated the outcomes of curative-intent pulmonary resection for NSCLC patients with synchronous isolated bone metastases, which have been less clear to date. We retrospectively reviewed the clinical and pathological records of 41 patients with NSCLC and synchronous isolated bone metastases who underwent radical treatments (surgery and/or chemotherapy and/or radiotherapy) for both their primary tumors and bone metastases at the National Hospital Organization, Hokkaido Cancer Center, between 2008 and 2013. Nine of the 41 patients underwent pulmonary primary tumor resection; the rate of clinical N0-1 disease among these 9 patients (100%) was significantly higher than that among the 32 patients who did not undergo resection (34.4%). The five-year overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) rates of the nine patients who underwent pulmonary resection were 66.7%, 55.6%, and 44.4%, respectively. On multivariate analysis, the predictors of longer OS among all 41 patients were primary site resection [hazard ratio (HR) =4.18, 95% CI, 1.20-14.6, P=0.025] and epidermal growth factor receptor (EGFR) mutation (HR =3.30, 95% CI, 1.08-10.1, P=0.036). The former was also a predictor of longer PFS (HR =3.75, 95% CI, 1.27-11.0, P=0.016). Patients with clinical N0-1 NSCLC and synchronous isolated bone metastases may achieve longer survival rates following primary lung tumor resection.
Sections du résumé
BACKGROUND
BACKGROUND
The efficacy of curative-intent pulmonary resection for non-small cell lung cancer (NSCLC) patients with certain types of oligometastases, particularly brain and adrenal metastases, has previously been described. We investigated the outcomes of curative-intent pulmonary resection for NSCLC patients with synchronous isolated bone metastases, which have been less clear to date.
METHODS
METHODS
We retrospectively reviewed the clinical and pathological records of 41 patients with NSCLC and synchronous isolated bone metastases who underwent radical treatments (surgery and/or chemotherapy and/or radiotherapy) for both their primary tumors and bone metastases at the National Hospital Organization, Hokkaido Cancer Center, between 2008 and 2013.
RESULTS
RESULTS
Nine of the 41 patients underwent pulmonary primary tumor resection; the rate of clinical N0-1 disease among these 9 patients (100%) was significantly higher than that among the 32 patients who did not undergo resection (34.4%). The five-year overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) rates of the nine patients who underwent pulmonary resection were 66.7%, 55.6%, and 44.4%, respectively. On multivariate analysis, the predictors of longer OS among all 41 patients were primary site resection [hazard ratio (HR) =4.18, 95% CI, 1.20-14.6, P=0.025] and epidermal growth factor receptor (EGFR) mutation (HR =3.30, 95% CI, 1.08-10.1, P=0.036). The former was also a predictor of longer PFS (HR =3.75, 95% CI, 1.27-11.0, P=0.016).
CONCLUSIONS
CONCLUSIONS
Patients with clinical N0-1 NSCLC and synchronous isolated bone metastases may achieve longer survival rates following primary lung tumor resection.
Identifiants
pubmed: 31656656
doi: 10.21037/jtd.2019.09.17
pii: jtd-11-09-3836
pmc: PMC6790437
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3836-3845Informations de copyright
2019 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Clin Transl Oncol. 2013 Oct;15(10):802-9
pubmed: 23430537
J Thorac Oncol. 2012 Dec;7(12):1807-1814
pubmed: 23154552
J Thorac Oncol. 2012 Oct;7(10):1547-55
pubmed: 22982655
J Oncol Pract. 2010 Jan;6(1):39-43
pubmed: 20539732
Thorac Cancer. 2018 Aug;9(8):1012-1017
pubmed: 29924498
J Clin Oncol. 1995 Jan;13(1):8-10
pubmed: 7799047
Ann Transl Med. 2018 Mar;6(5):93
pubmed: 29666816
J Thorac Cardiovasc Surg. 2012 Aug;144(2):444-52
pubmed: 22713303
Med Sci Monit. 2017 Aug 24;23:4087-4094
pubmed: 28835603
Clin Pharmacol Ther. 2017 Nov;102(5):757-764
pubmed: 28786099
Cancer Med. 2018 Oct;7(10):5015-5026
pubmed: 30239162
Eur Respir Rev. 2013 Mar 1;22(127):33-6
pubmed: 23457162
Ann Thorac Surg. 2019 Apr;107(4):1053-1059
pubmed: 30476480
Oncotarget. 2017 Apr 11;8(15):25691-25699
pubmed: 28148890
Ann Thorac Surg. 2014 Jul;98(1):258-64
pubmed: 24746441
Ann Thorac Surg. 2017 May;103(5):1594-1599
pubmed: 27863731
J Thorac Dis. 2017 Jul;9(7):1903-1910
pubmed: 28839988
BMC Cancer. 2014 Jun 10;14:416
pubmed: 24913188
Ann Thorac Surg. 2014 Jul;98(1):249-56
pubmed: 24820385